环状RNA circTADA2A通过与TRIM28相互作用稳定p53并抑制FLT3-ITD急性髓系白血病的维持
本文研究circTADA2A在FLT3-ITD急性髓系白血病(AML)中的作用及治疗潜力。circTADA2A在FLT3-ITD AML患者中下调,其下调对AML细胞增殖、白血病维持及白血病干/起始细胞自我更新至关重要。机制上circTADA2A竞争性结合TRIM28抑制TRIM28/MDM2复合物形成,降低p53泛素化并激活p53通路;体外转录circTADA2A并经脂质纳米颗粒体内递送联合quizartinib可增强清除FLT3-ITD白血病细胞。
要点
- circTADA2A在FLT3-ITD AML患者中下调,其下调对AML细胞增殖和LSCs/LICs自我更新至关重要。
- circTADA2A竞争性结合TRIM28,抑制TRIM28/MDM2复合物形成,降低p53泛素化并激活p53通路。
- 体外转录circTADA2A经LNPs体内递送联合quizartinib可增强清除FLT3-ITD白血病细胞。
核心结论
- circTADA2A在FLT3-ITD AML维持中发挥关键作用,并提示一种具有转化价值的circTADA2A治疗策略。
研究设计与样本
- 研究采用FLT3-ITD AML患者样本及人FLT3-ITD AML细胞,开展circTADA2A功能与机制研究,并进行体外转录circTADA2A经LNPs体内递送联合quizartinib治疗的实验。
主要发现
- circTADA2A在FLT3-ITD AML患者中下调。
- circTADA2A下调对FLT3-ITD AML细胞增殖、AML维持及LSCs/LICs自我更新至关重要。
- circTADA2A通过竞争性结合TRIM28抑制TRIM28/MDM2复合物形成,降低p53泛素化水平并激活p53通路。
- 体外转录circTADA2A及经LNPs体内递送联合quizartinib治疗可显著增强清除FLT3-ITD白血病细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Internal tandem duplication mutations in the FMS-like tyrosine kinase 3 (FLT3-ITDs) occur in 25%-30% of acute myeloid leukemia (AML) cases and are associated with adverse prognosis. RNA-based therapeutics exhibit significant potential for treating diseases, prompting us to develop a novel circular RNA (circRNA)-based therapeutic strategy for FLT3-ITD AML. Here, we find circTADA2A is downregulated in FLT3-ITD AML patients. We further demonstrate that the downregulation of circTADA2A is critical for the proliferation of human FLT3-ITD AML cells, the sustenance of AML, and the self-renewal of leukemia stem/initiating cells (LSCs/LICs). Mechanistically, circTADA2A inhibits the TRIM28/MDM2 complexes formation by competitively binding to TRIM28, resulting in decreased levels of p53 ubiquitination and activating the p53 pathway. Importantly, in vitro transcription of circTADA2A and in vivo delivery via lipid nanoparticles (LNPs) significantly enhance the elimination of FLT3-ITD leukemia cells in combination with quizartinib treatment. In conclusion, our work uncovers the crucial functions of circTADA2A in the maintenance of FLT3-ITD AML and highlights a translationally important circTADA2A-based therapeutic approach for FLT3-ITD AML treatment.
引用
- Li R, Wu X, Xue K, et al. CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia. Leukemia. 2025. PMID: 40175625. doi:10.1038/s41375-025-02589-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。